EICHOR
● Active Not Recruiting
PALbociclib CoLlaborative Adjuvant Study
Condition: Breast Cancer · Sponsor: Alliance Foundation Trials, LLC.
About this study
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (437)
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Southern Cancer Center PC - Providence | Mobile, Alabama, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Cancer Center | Anchorage, Alaska, United States | — |
| Mayo Clinic in Arizona | Phoenix, Arizona, United States | — |
| Kaiser Permanente Anaheim Medical Center | Anaheim, California, United States | — |
| Kaiser Permanente Baldwin Park Medical Center | Baldwin Park, California, United States | — |
| Kaiser Permanente Bellflower Medical Center | Bellflower, California, United States | — |
| Kaiser Permanente Fontana Medical Center | Fontana, California, United States | — |
| Marin Cancer Care | Greenbrae, California, United States | — |
| Marin Cancer Center | Greenbrae, California, United States | — |
| Kaiser Permanente Harbor City Medical Center | Harbor City, California, United States | — |
+ 425 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02513394